Public health issues of hepatitis C virus infection.

[1]  D. Holtzman,et al.  Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. , 2012, Annals of internal medicine.

[2]  N. Pai,et al.  Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.

[3]  Michael J. O'Grady,et al.  Economic model of a birth cohort screening program for hepatitis C virus , 2012, Hepatology.

[4]  P. Grime,et al.  Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data , 2012, Journal of viral hepatitis.

[5]  J. Ward,et al.  The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings , 2012, Annals of Internal Medicine.

[6]  Peter J. Richardson,et al.  Gaps in the achievement of effectiveness of HCV treatment in national VA practice. , 2012, Journal of hepatology.

[7]  C. Mcgowan,et al.  Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[8]  D. Berg.  3.13.1 THE EUROPEAN EXPERIENCE , 2012 .

[9]  P. Vickerman,et al.  Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.

[10]  G. Torre,et al.  Hepatitis C Virus infections trends in Italy, 1996-2006 , 2011, Hepatitis monthly.

[11]  M. Alter.  HCV routes of transmission: what goes around comes around. , 2011, Seminars in liver disease.

[12]  M. Buti,et al.  The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * , 2011, Journal of viral hepatitis.

[13]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[14]  M. Buti,et al.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Joan M. Block,et al.  Is chronic hepatitis B being undertreated in the United States? , 2011, Journal of viral hepatitis.

[16]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  P. Vickerman,et al.  Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.

[18]  Axel Rahmel,et al.  The European experience , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  M. Alter,et al.  Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. , 2011, Archives of internal medicine.

[20]  S. Smith,et al.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression , 2010, Alimentary pharmacology & therapeutics.

[21]  S. Holmberg,et al.  Is sexual contact a major mode of hepatitis C virus transmission? , 2010, Hepatology.

[22]  H. M. Colvin,et al.  Institute of Medicine recommendations for the prevention and control of hepatitis B and C , 2010, Hepatology.

[23]  M. Alter,et al.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. , 2010, Gastroenterology.

[24]  J. Desenclos,et al.  The impact of the prevention programme of hepatitis C over more than a decade: the French experience , 2009, Journal of viral hepatitis.

[25]  A. Valleron,et al.  Modelling the past, current and future HCV burden in France: detailed analysis and perspectives , 2009, Statistical methods in medical research.

[26]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[27]  D. Lavanchy,et al.  The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[28]  D. Vlahov,et al.  Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.

[29]  J. Desenclos,et al.  Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. , 2008, Journal of hepatology.

[30]  D. De Angelis,et al.  The burden of hepatitis C in England , 2007, Journal of viral hepatitis.

[31]  M. Alter,et al.  Epidemiology of hepatitis C virus infection. , 2007, World journal of gastroenterology.

[32]  M. Alter,et al.  Infectivity of Hepatitis C Virus in Plasma After Drying and Storing at Room Temperature , 2007, Infection Control & Hospital Epidemiology.

[33]  K. Neal.  Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study , 2007, Gut.

[34]  J B Wong,et al.  Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States , 2007, Journal of viral hepatitis.

[35]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[36]  L. Fraenkel,et al.  What do patients consider when making decisions about treatment for hepatitis C? , 2005, The American journal of medicine.

[37]  A. Hatzakis,et al.  Future trends of HCV‐related cirrhosis and hepatocellular carcinoma under the currently available treatments , 2005 .

[38]  M. Buti,et al.  Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. , 2005, Journal of hepatology.

[39]  G. Dore,et al.  Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  R. Zachoval,et al.  Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[42]  S. Mauss,et al.  A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.

[43]  S. Zickmund,et al.  Hepatitis C virus‐infected patients report communication problems with physicians , 2004, Hepatology.

[44]  Y. Hutin,et al.  The global burden of disease attributable to contaminated injections given in health care settings , 2004, International journal of STD & AIDS.

[45]  G. Davis,et al.  Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[46]  A. Lok,et al.  Identification and Management of Hepatitis C Patients in Primary Care Clinics , 2003, American Journal of Gastroenterology.

[47]  John B. Wong,et al.  Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C , 2003 .

[48]  E. Roberts,et al.  Maternal‐infant transmission of hepatitis C virus infection , 2002, Hepatology.

[49]  S. Sonnad,et al.  Management of hepatitis C patients by primary care physicians in the USA: results of a national survey , 2001, Journal of viral hepatitis.

[50]  M. Backmund,et al.  Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.

[51]  M. Buti,et al.  Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. , 2000, Journal of hepatology.

[52]  M. Abdel-hamid,et al.  Hepatitis C virus (HCV) infection in a community in the nile delta: Population description and HCV prevalence , 2000, Hepatology.

[53]  L. Magder,et al.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.

[54]  F. Gordon,et al.  Cost-effectiveness of screening patients for hepatitis C. , 1999, The American journal of medicine.

[55]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[56]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[57]  M. Jadoul,et al.  Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission. , 2012, Contributions to nephrology.

[58]  R. Elston,et al.  Oral combination therapy: Future hepatitis C virus treatment? , 2011 .

[59]  D. Harnois,et al.  Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .

[60]  A. Hatzakis,et al.  Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. , 2004, Journal of viral hepatitis.

[61]  M. Manns,et al.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. , 2003, Gut.

[62]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.

[63]  G. Cilla,et al.  Maternal-infant transmission of hepatitis C virus infection. , 1992, The Pediatric infectious disease journal.